CD2AP and nonpapillary renal cell carcinoma: Mass spectrometry was used to detect methylation status of the promoter CpG site of CD2AP in multiple cells.<h4>Results</h4>We found that CD2AP expression was downregulated in ccRCC and its lower expression level was correlation with worse patient prognosis, higher tumor stage and grade and distant metastasis through analysis of databases, ccRCC cell lines and clinical tissue samples.